Robert Z. Orlowski, MD, PhD

home / authors / robert-z-orlowski-md-phd

Articles

Management of Bispecific Toxicities and Final Thoughts on Treatments in MM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

March 6th 2023

Closing out the panel discussion, experts review the management of bispecific-related toxicities and share their final thoughts on treating patients with multiple myeloma.

The Role of Belantamab Mafodotin and Its Impact on Future Treatment Options

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

March 6th 2023

Expert oncologists discuss Belantamab mafodotin, its recent withdrawal from the U.S. market, and the clinical implications of the DREAMM trials for patients with R/R multiple myeloma.

Rationale for Bispecific-Based Combinations in MM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

February 27th 2023

Shared perspective on the potential role of ADCs, CAR T-cell therapy, and other agents in combination treatment with bispecifics for patients with multiple myeloma.

Treatment Selection of Bispecifics in Relapsed-Refractory MM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

February 27th 2023

Focusing their discussion on clinical data in R/R multiple myeloma studies, panelists highlight current and emerging bispecific antibodies for treating patients that have progressed after multiple lines of therapy.

Treatment Approaches for Patients with Relapsed-Refractory MM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

February 20th 2023

Expert panelists discuss treatment approaches for patient with multiple myeloma that have progressed and are relapsed and/or refractory (R/R).

Final Thoughts on Transplant-Ineligible Patients with MM

Robert Z. Orlowski, MD, PhD;C. Ola Landgren, MD, PhD;Amrita Y. Krishnan, MD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

February 20th 2023

Experts offer final thoughts on the treatment of newly diagnosed MM for patients that are transplant-ineligible.

Review of Patient Subgroups in Transplant-Ineligible NDMM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

February 13th 2023

Oncology expert panelists review patient subgroup analyses for MAIA and SWOG0777 studies, investigating treatments for transplant-ineligible patients with newly diagnosed multiple myeloma.

Clinical Trials in Transplant-Ineligible NDMM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

February 13th 2023

Expert panelists review clinical data from studies investigating treatment regimens for patients with NDMM that are transplant-ineligible.

Induction Therapy in Transplant-Ineligible NDMM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

February 6th 2023

A panel of expert oncologists consider treatment options for patients with NDMM that are transplant-ineligible.

Role of Transplant and Induction Therapies in NDMM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

February 6th 2023

Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).

DETERMINATION, GRIFFIN, and MASTER Studies

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

January 30th 2023

Expert panelists discuss recent data updates from the DETERMINATION, GRIFFIN, and MASTER studies.

Induction Regimen Options in Transplant-Eligible NDMM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

January 30th 2023

Opening their discussion on transplant-eligible newly diagnosed multiple myeloma (NDMM), expert panelists review induction regimen options for patients.

Unmet Needs and Future Perspectives in Multiple Myeloma Treatment

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 21st 2022

A look at the unmet needs and future directions of multiple myeloma treatment.

Novel Agents Under Investigation for Multiple Myeloma

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 21st 2022

Oncologists highlight novel agents currently being investigated for the treatment of relapsed/refractory multiple myeloma.

$CAR-T Therapies in Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 and KarMMA Studies$

CAR-T Therapies in Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 and KarMMA Studies

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 19th 2022

Key takeaways from the CARTITUDE-1 study and the KarMMA study evaluating CAR T-cell therapies for relapsed/refractory multiple myeloma.

$BCMA-Targeting Bispecific Agents for Relapsed/Refractory Multiple Myeloma Treatment$

BCMA-Targeting Bispecific Agents for Relapsed/Refractory Multiple Myeloma Treatment

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 19th 2022

An overview of BCMA-targeting bispecific agents in development for multiple myeloma, including talquetamab and teclistamab.

$Novel BCMA-Targeting Agents for the Treatment of Relapsed/Refractory Multiple Myeloma$

Novel BCMA-Targeting Agents for the Treatment of Relapsed/Refractory Multiple Myeloma

Rafael Fonseca, MD;Krina K. Patel, MD;Caitlin Costello, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 19th 2022

A panel of doctors discuss the available treatment options for early and late relapsed multiple myeloma, including approved novel BCMA-targeting agents.

Outcomes with Daratumumab in Frontline Versus Subsequent Lines of Therapy in Transplant-Ineligible MM

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 19th 2022

A look at the patient outcomes with daratumumab use in the frontline vs second-line setting in patients with transplant-ineligible multiple myeloma, and the pros and cons of subcutaneous vs intravenous daratumumab.

First-Line Treatment Options for Transplant-Ineligible NDMM: Focus on MAIA Trial

Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD;Rafael Fonseca, MD

April 4th 2022

A review of the available first-line treatment options for transplant-ineligible multiple myeloma, as well as the design and findings of the MAIA study.

Treatment Duration and Response to Induction Therapy in Transplant-Eligible NDMM

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

April 4th 2022

Experts explain how to determine treatment duration and a successful response to induction therapy for transplant-eligible multiple myeloma.

Choosing Between Triplet and Quadruplet Induction Regimens for Transplant-Eligible NDMM

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

March 25th 2022

A discussion on choosing between triplet or quadruplet induction therapy for transplant-eligible newly diagnosed multiple myeloma.

Triplet and Quadruplet Induction Regimens for Transplant-Eligible NDMM: Focus on GRIFFIN and MASTER Trials

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

March 25th 2022

An overview of the triplet and quadruplet induction treatment regimens available for patients with transplant-eligible multiple myeloma and key clinical trials studying daratumumab and isatuximab presented at ASH 2021, with emphasis on the GRIFFIN, MASTER and GMMG-HD7 studies.

Transplant-Ineligible MM: Navigating Treatment Challenges

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 15th 2021

A panel of hematologists/oncologists conclude a discussion about transplant-ineligible multiple myeloma (MM) by reacting to current treatment gaps that need to be addressed.

Counseling Patients With MM About Treatment Duration

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 13th 2021

Recommendations when talking with patients with transplant-ineligible multiple myeloma (MM) who request to stop receiving treatment.

Transplant-Ineligible MM: Reinitiating Therapy

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 8th 2021

Triggers that may lead a hematologist/oncologist to consider reinstituting therapy for a patient with transplant-ineligible multiple myeloma (MM) who received prior therapy but was not treated to progression.

Transplant-Ineligible MM: Treating to Progression

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 6th 2021

The rationale behind treating patients with newly diagnosed transplant-ineligible multiple myeloma (MM) until disease progression rather than stopping therapy at a designated point in time.

Maintenance Therapy for Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

October 1st 2021

Take-home points from the MAIA trial of daratumumab plus lenalidomide and dexamethasone as therapy for patients with newly diagnosed transplant-ineligible multiple myeloma, and recommendations regarding maintenance therapy following the use of a triplet regimen.

Triplet Vs Doublet Therapy for Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 29th 2021

Scenarios for which a doublet regimen may be recommended over a triplet therapy for the management of newly diagnosed transplant-ineligible multiple myeloma.

Managing A Case of Newly-Diagnosed Transplant-Ineligible MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 24th 2021

A panel of hematologist-oncologists comment on how they would treat a 74-year-old patient with newly diagnosed transplant-ineligible multiple myeloma.

Managing Adequate/Inadequate Treatment Response in MM

Robert Z. Orlowski, MD, PhD;Larry Anderson, MD, PhD, FACP;Caitlin Costello, MD;Jeffrey V. Matous, MD

September 22nd 2021

Recommended next steps regarding treatment for patients with transplant-ineligible multiple myeloma based on prior responses to therapy.

1 2 >